Bio-Rad Laboratories Company Profile (NYSE:BIO)

About Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories logoBio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NYSE:BIO
  • CUSIP: 09057220
  • Web:
  • Market Cap: $6.96132 billion
  • Outstanding Shares: 29,605,000
Average Prices:
  • 50 Day Moving Avg: $226.84
  • 200 Day Moving Avg: $208.56
  • 52 Week Range: $143.26 - $238.00
  • Trailing P/E Ratio: 249.92
  • Foreward P/E Ratio: 53.14
  • P/E Growth: 5.18
Sales & Book Value:
  • Annual Revenue: $2.1 billion
  • Price / Sales: 3.32
  • Book Value: $91.45 per share
  • Price / Book: 2.57
  • EBIDTA: $271.79 million
  • Net Margins: 1.35%
  • Return on Equity: 3.23%
  • Return on Assets: 2.19%
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 4.25%
  • Quick Ratio: 2.88%
  • Average Volume: 150,311 shs.
  • Beta: 0.91
  • Short Ratio: 4.52
Frequently Asked Questions for Bio-Rad Laboratories (NYSE:BIO)

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its earnings results on Thursday, May, 4th. The company reported $0.41 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.27 by $0.14. The company earned $500.05 million during the quarter, compared to the consensus estimate of $477.76 million. Bio-Rad Laboratories had a net margin of 1.35% and a return on equity of 3.23%. The company's revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.42 earnings per share. View Bio-Rad Laboratories' Earnings History.

When will Bio-Rad Laboratories make its next earnings announcement?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, August, 3rd 2017. View Earnings Estimates for Bio-Rad Laboratories.

Where is Bio-Rad Laboratories' stock going? Where will Bio-Rad Laboratories' stock price be in 2017?

4 equities research analysts have issued 12-month price objectives for Bio-Rad Laboratories' stock. Their forecasts range from $180.00 to $275.00. On average, they expect Bio-Rad Laboratories' share price to reach $225.00 in the next year. View Analyst Ratings for Bio-Rad Laboratories.

What are analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:

  • 1. According to Zacks Investment Research, "Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. " (7/5/2017)
  • 2. Jefferies Group LLC analysts commented, "Time to forget everything you thought you knew about BIO -- as two separate updates y'day included several "firsts" that add conviction to our bullish thesis: 1) 2020 rev & margin goals; 2) capital allocation plan opens the door for buybacks; 3) board shuffle / quality upgrade. Bottom line: the pathway to $300+ in 2-3 yrs just got a lot clearer & BIO's new shareholder-friendly behavior eliminates the rationale for a structural valuation discount, in our view." (3/14/2017)

Who are some of Bio-Rad Laboratories' key competitors?

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:

  • Norman D. Schwartz, Chairman of the Board, President, Chief Executive Officer
  • Christine A. Tsingos, Chief Financial Officer, Executive Vice President
  • John P. Goetz, Chief Operating Officer, Executive Vice President
  • Timothy Scott Ernst, Executive Vice President, General Counsel and Secretary
  • Michael Crowley, Executive Vice President, Global Commercial Operations
  • Shannon Hall, Executive Vice President, President, Life Science Group
  • John Hertia, Executive Vice President, President, Clinical Diagnostics Group
  • Giovanni Magni, Executive Vice President, Chief Strategy Officer
  • Ronald W. Hutton, Vice President, Treasurer
  • Alice N. Schwartz, Director

Who owns Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (3.02%), Fisher Asset Management LLC (0.94%), Hermes Investment Management Ltd. (0.68%), Russell Investments Group Ltd. (0.36%), Assenagon Asset Management S.A. (0.22%) and Aperio Group LLC (0.06%). Company insiders that own Bio-Rad Laboratories stock include James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories.

Who sold Bio-Rad Laboratories stock? Who is selling Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Hermes Investment Management Ltd., First Quadrant L P CA, Quantitative Systematic Strategies LLC, Acadian Asset Management LLC, Parametrica Management Ltd, Huntington National Bank, BTR Capital Management Inc. and Capstone Asset Management Co.. Company insiders that have sold Bio-Rad Laboratories stock in the last year include James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories.

Who bought Bio-Rad Laboratories stock? Who is buying Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bank of Montreal Can, Fisher Asset Management LLC, Russell Investments Group Ltd., ING Groep NV, Aperio Group LLC, Oakbrook Investments LLC and Creative Planning. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy Bio-Rad Laboratories stock?

Shares of Bio-Rad Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of Bio-Rad Laboratories stock can currently be purchased for approximately $235.42.

MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bio-Rad Laboratories (NYSE:BIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $225.00 (4.43% downside)

Analysts' Ratings History for Bio-Rad Laboratories (NYSE:BIO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Jefferies Group LLCReiterated RatingBuy$275.00LowView Rating Details
7/13/2017Wells Fargo & CompanyInitiated CoverageOutperform -> Outperform$250.00HighView Rating Details
6/28/2017Deutsche Bank AGUpgradeHold -> Buy$220.00 -> $195.00HighView Rating Details
10/12/2016CL KingInitiated CoverageBuy$180.00N/AView Rating Details
11/4/2015Leerink SwannBoost Price Target$143.00 -> $149.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Bio-Rad Laboratories (NYSE:BIO)
Earnings by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Earnings History by Quarter for Bio-Rad Laboratories (NYSE BIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017$0.49N/AView Earnings Details
5/4/2017Q1 2017$0.27$0.41$477.76 million$500.05 millionViewListenView Earnings Details
2/23/2017Q416$1.03($0.70)$574.40 million$571.45 millionViewN/AView Earnings Details
11/1/2016Q316$0.51$0.62$480.60 million$508.75 millionViewN/AView Earnings Details
8/3/2016Q2$1.13$0.61$497.80 million$516.80 millionViewN/AView Earnings Details
5/5/2016Q1$0.60$0.42$463.90 million$471.20 millionViewN/AView Earnings Details
2/25/2016Q415$1.27$1.68$570.80 million$570.56 millionViewListenView Earnings Details
11/3/2015Q315$0.54$0.59$495.55 million$469.96 millionViewN/AView Earnings Details
8/6/2015Q215$0.78$0.97$494.85 million$506.10 millionViewN/AView Earnings Details
5/5/2015Q115$0.33$0.61$474.60 million$472.80 millionViewN/AView Earnings Details
2/26/2015Q414$1.18$1.34$593.41 million$598.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.86$0.39$525.40 million$530.64 millionViewN/AView Earnings Details
8/5/2014Q214$0.95$1.09$537.58 million$536.80 millionViewN/AView Earnings Details
5/6/2014Q114$0.80$0.23$515.00 million$509.30 millionViewN/AView Earnings Details
2/27/2014Q413$1.42$1.04$586.67 million$602.60 millionViewListenView Earnings Details
11/7/2013Q313$0.91($0.25)$529.02 million$505.10 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.25$1.20$532.60 million$525.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.03$0.68$506.34 million$499.70 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.33$1.65$558.68 million$573.80 millionViewN/AView Earnings Details
11/6/2012Q312$1.14$1.48$507.79 million$498.70 millionViewN/AView Earnings Details
8/7/2012$1.19$1.69ViewN/AView Earnings Details
5/1/2012$1.02$1.09ViewN/AView Earnings Details
2/23/2012$1.67$2.08ViewN/AView Earnings Details
11/1/2011$1.53$1.61ViewN/AView Earnings Details
8/2/2011$1.47$1.41ViewN/AView Earnings Details
5/3/2011$1.32$1.16ViewN/AView Earnings Details
2/24/2011$1.35$2.41ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bio-Rad Laboratories (NYSE:BIO)
2017 EPS Consensus Estimate: $3.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.41$0.41$0.41
Q2 20171$0.81$0.81$0.81
Q3 20171$0.50$0.50$0.50
Q4 20171$1.40$1.40$1.40
Q1 20181$1.05$1.05$1.05
Q2 20181$1.33$1.33$1.33
Q3 20181$1.06$1.06$1.06
(Data provided by Zacks Investment Research)


Dividend History for Bio-Rad Laboratories (NYSE:BIO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Rad Laboratories (NYSE:BIO)
Insider Ownership Percentage: 28.29%
Institutional Ownership Percentage: 63.90%
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/7/2017Michael CrowleyEVPSell300$196.13$58,839.00View SEC Filing  
11/9/2016James R. StarkVPSell1,299$171.42$222,674.58View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Bio-Rad Laboratories (NYSE:BIO)
Latest Headlines for Bio-Rad Laboratories (NYSE:BIO)
DateHeadline logoMultiplexed Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 - July 21 at 11:12 PM logoGlobal Microbiology & Bacterial Culture for Industrial Testing Market Analysis 2014-2025 - Innovations and Advancing Microbiology Research in Context With Media & Reagents ... - July 21 at 11:12 PM logoJefferies Group LLC Reaffirms "Buy" Rating for Bio-Rad Laboratories, Inc. (BIO) - July 15 at 4:14 PM logoIn Vitro Diagnostics Quality Control Market by Application, Source, Type - Global Forecast to 2022 - July 14 at 3:42 AM logoMicrobiological Testing of Water Market is projected to reach USD 1.59 billion by 2022 - July 14 at 3:42 AM logoBio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Recommendation of "Buy" from Brokerages - July 13 at 8:28 AM logoBio-Rad Laboratories, Inc. (NYSE:BIO) Expected to Post Quarterly Sales of $515.04 Million - July 12 at 9:14 AM logoBio-Rad Laboratories, Inc. (BIO) Expected to Announce Earnings of $0.55 Per Share - July 10 at 10:24 PM logoBio-Rad to Report Second-Quarter 2017 Financial Results Thursday, August 3, 2017 - July 10 at 9:36 PM logoIn Vitro Diagnostics (IVD) Quality Control Market Worth 1.04 Billion USD by 2022 - July 7 at 2:14 AM logoBio-Rad Laboratories Inc. (BIO) Rose Past Resistance At The Highs - July 6 at 4:08 PM logoBio-Rad Laboratories, Inc. (BIO) Cut to Hold at Zacks Investment Research - July 5 at 5:34 PM logoBiochips (Microarrays/Microfluidics) Global Market â€" Forecast To 2023 - June 30 at 3:45 AM logoWith 'Tunnel's End' In Sight, Deutsche Upgrades Bio-Rad Labs - June 28 at 3:18 PM logoAdamas Appoints New Chief Financial Officer - June 28 at 3:18 PM logoBio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO-US : June 28, 2017 - June 28 at 3:18 PM logoBio-Rad Laboratories, Inc. (BIO) Upgraded by Deutsche Bank AG to "Buy" - June 28 at 8:19 AM logoSingle-cell Analysis Market is expected to reach USD 3.59 billion by 2022 - June 26 at 4:31 PM logoBio-Rad Laboratories, Inc. (BIO) Rating Increased to Buy at BidaskClub - June 24 at 2:26 PM logoMicrobiological Testing of Water Market Worth 1.59 Billion USD by 2022 - June 24 at 6:07 AM logoBio-Rad (BIO) Scores a Strong Buy Right Now: Here's How - June 22 at 11:42 AM logoZacks: Bio-Rad Laboratories, Inc. (BIO) Given Consensus Recommendation of "Buy" by Analysts - June 21 at 6:32 PM logoGlobal Cancer Tissue Diagnostics Market to Increase at a CAGR of 8.3% Over the Forecast Period (2016-2026) - June 19 at 4:04 PM logoETFs with exposure to Bio-Rad Laboratories, Inc. : June 19, 2017 - June 19 at 4:04 PM logoBio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 - June 16 at 4:39 PM logoBio-Rad Laboratories, Inc. (BIO) Expected to Post Quarterly Sales of $515.04 Million - June 16 at 1:32 PM logoBio-Rad Laboratories, Inc. (BIO) Downgraded to Hold at BidaskClub - June 14 at 11:32 PM logoZacks: Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Announce Earnings of $0.55 Per Share - June 14 at 10:32 PM logoBRIEF-Bio Rad Laboratories receives FDA clearance for Bioplex 2200 syphilis total & RPR assay - June 13 at 1:04 PM logoBio-Rad Announces FDA Clearance of its BioPlex 2200 Syphilis Total & RPR Assay, a Novel Syphilis Testing Method - June 12 at 4:56 PM logoCritical Analysis: Bio-Rad Laboratories (BIO) vs. WaferGen Bio-systems (WGBS) - June 4 at 4:50 PM logoComparing InVitae Corp (NVTA) & Bio-Rad Laboratories (BIO) - June 4 at 10:16 AM logoImprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13% - June 2 at 5:19 PM logoIVD Market in BRIC is expected to reach USD 15.71 billion by 2022 - May 31 at 9:01 PM logoZacks: Bio-Rad Laboratories, Inc. (BIO) Given $238.33 Average Price Target by Analysts - May 31 at 8:32 AM logoProtein Assays Market Growing at a CAGR of 11.1% During 2017 to 2022 - ReportsnReports - May 30 at 3:57 PM logoProtein Assays Market Worth 2.41 Billion USD by 2022 - May 25 at 1:54 AM logoBio-Rad Introduces Enhanced Options with its IH-Com Data Management Software for Managing Patient Results with the IH-1000 System - May 24 at 8:51 PM logoInside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017 - May 22 at 3:52 PM logoInside Bio-Rad Laboratories’ Profit Margin Expectations in 2017 - May 22 at 3:52 PM logoBio-Rad Laboratories on the Street: Analysts’ Recommendations in May - May 22 at 11:29 AM logo Bio-Rad Laboratories, Inc. (BIO) Receives Average Rating of "Buy" from Analysts - May 16 at 6:42 PM logoIn Vitro Diagnostics (IVD) Market in BRIC Growing at a CAGR of 8.2% During 2017 to 2022 - ReportsnReports - May 15 at 4:04 PM logoSTERIS (STE) Grapples with Headwinds: Should You Dump? - May 12 at 4:30 PM logoMedtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite - May 12 at 4:30 PM logoJefferies Group Research Analysts Decrease Earnings Estimates for Bio-Rad Laboratories, Inc. (BIO) - May 8 at 9:06 AM logoBio-Rad Laboratories, Inc. (BIO) Releases Earnings Results, Beats Estimates By $0.14 EPS - May 5 at 8:08 PM logoEdited Transcript of BIO earnings conference call or presentation 4-May-17 9:00pm GMT - May 5 at 3:56 PM logoBio-Rad Laboratories (BIO) Q1 2017 Results - Earnings Call Transcript - May 5 at 2:04 AM logoBio-Rad Reports First-Quarter 2017 Financial Results - May 4 at 9:04 PM



Bio-Rad Laboratories (BIO) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff